Pharmaceutical stocks changed, Huahai Pharmaceutical, Haisco and other pharmaceutical companies rose to the limit

Data show that on December 28, 922 stocks rose among the tradable A shares in Shanghai and Shenzhen
.
Excluding new stocks listed on the same day, a total of 39 stocks were limited to the limit, mainly in the pharmaceutical and biotechnology, leisure services, utilities, media and other industries
.
From the perspective of pharmaceutical stocks, today's companies with a limit of price include Huahai Pharmaceutical, Haisco and so on
.
Among them, at 9:52 on December 28, Huahai Pharmaceutical opened the intraday limit and is now reported at 21.
79 yuan, with a transaction of 665 million yuan and a turnover rate of 2.
15%.

The stock had previously traded at 9:51 a.
m.

According to the data, Huahai Pharmaceutical is a company
mainly engaged in the production and sales of APIs, pharmaceutical intermediates and preparations.
The company's main products are pril, sartan and other hypertension APIs
.
On the news, the Geneva Medicines Patent Pool Organization announced that it has signed agreements with 35 pharmaceutical companies to allow them to produce one of Pfizer's Paxlovid ingredients, nematevir APIs or preparations
.
According to information released by MPP, there are 5 Chinese companies among the 35 companies that signed the agreement with MPP, namely Shanghai Disano, Huahai Pharmaceutical, Propharma, Fosun Pharma and Jiuzhou Pharmaceutical
.
It is reported that Huahai Pharmaceutical is a domestic characteristic API industry enterprise, and the innovative drug recombinant human vascular endothelial growth factor receptor-antibody fusion protein ophthalmic injection has been declared for clinical use for
age-related macular degeneration.
Huahai Pharmaceutical has successively established two biopharmaceutical companies, Huabo Biotechnology and Huaotai Biotechnology, as well as Cesselqing Biotechnology, which constitute the company's biomedical segment
.
The analysis pointed out that the stock touched the limit today, and the market may continue to have high momentum in the future
.
The data shows that in terms of the capital flow data of Huahai Pharmaceutical on December 28, the net inflow of main funds was 316 million yuan, accounting for 20.
7% of the total turnover, the net outflow of floating funds was 242 million yuan, accounting for 15.
86% of the total turnover, and the net outflow of retail funds was 73.
9532 million yuan, accounting for 4.
84% of
the total turnover.
At 10:42 on December 28, Haisco rose intraday to 22.
52 yuan, and the current closed order is 121289 lots, equivalent to 273 million yuan
.
Up to now, the transaction has been 91.
0428 million yuan, with a turnover rate of 0.
88%.

The stock has risen 4 times
in the past year.
The reason for Haisco's change was revealed: 1.
On December 27, Haisco submitted the marketing application of desonide cream with imitation of Class 3 and was accepted by CDE, which is a hormonal topical ointment, and only Chongqing Huabang Pharmaceutical has production approval in China
.
2.
The company has a subsidiary Chengdu Haisco Medical Equipment Co.
, Ltd.
, which previously subscribed for 8.
57% of the equity of aminate, the target of which is a new implantable medical device "VASQ" under development, ASQ is used for implantation in arteriovenous fistula creation surgery, providing support for AVF, etc.
; Introduced heart failure monitoring equipment and intelligent auxiliary equipment
for laparoscopic surgery from Israel.
3.
In May 20, the innovative drug HsK21542 injection obtained the "Clinical Trial Notice", and will carry out "clinical trials intended for the treatment of pruritus; It holds a 7.
67% stake in Hitron Pharmaceutical, which independently developed HC-1119 as a drug
for the treatment of prostate cancer and breast cancer.
The data shows that in terms of the capital flow data of Haisco on December 28, the net inflow of main funds was 21.
0982 million yuan, accounting for 19.
52% of the total turnover, the net outflow of floating funds was 12.
1047 million yuan, accounting for 11.
2% of the total turnover, and the net outflow of retail funds was 8.
9934 million yuan, accounting for 8.
32%
of the total turnover.
In addition, on December 28, China Pharmaceutical rose rapidly intraday, up more than 2% in 5 minutes, and as of 9:40, it was reported at 19.
55 yuan, with a transaction of 628 million yuan and a turnover rate of 2.
19%.

On December 28, Hongbo Pharma rose rapidly intraday, up more than 2% in 5 minutes, and as of 9:33, it was reported at 50.
79 yuan, with a transaction of 12.
2189 million yuan and a turnover rate of 1.
49%.

Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.